Date: 2014-09-25
Type of information: Termination of an agreement
Compound: pan-HDAC inhibitor compounds involving abexinostat
Company: Pharmacyclics (USA - CA) Servier (France)
Therapeutic area: Cancer - Oncology
Type agreement: termination of an R&D agreement
Action mechanism:
Disease:
Details: * On September 25, 2014, Pharmacyclics and Servier announced that they have mutually and amicably ended their collaboration pertaining to the ex-U.S. development of Pharmacyclics\' pan-HDAC inhibitor compounds involving abexinostat, thereby returning global development and commercialization rights to Pharmacyclics. A provisional patent application for abexinostat tosylate was filed with the U.S. Patent and Trademark Office in 2013 and, if issued, would extend patent protection until 2034. Pharmacyclics will evaluate the full opportunity that the compound may afford, and plans to provide an update on this program in mid 2015. In April 2009, Pharmacyclics and Servier have entered into a global strategic alliance to develop Pharmacyclics\' PCI-24781, an orally active, novel, small molecule inhibitor of Pan HDAC enzymes.
Financial terms:
Latest news:
